KYMR Kymera Therapeutics
- 46.880
- -0.860-1.80%
Kymera Therapeutics News
Insider Sale: Director at $KYMR (KYMR) Sells 2,500 Shares
Kymera Upped to Overweight by Wells Fargo on Upcoming Data
Kymera International Acquires Coating Center Castrop GmbH
Wells Fargo Upgrades Kymera Therapeutics(KYMR.US) to Buy Rating, Raises Target Price to $57
Express News | Wells Fargo Upgrades Kymera Therapeutics to Overweight, Raises Price Target to $57
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
Kymera Therapeutics (KYMR) Gets a Hold From Wells Fargo
There's Reason For Concern Over Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Price
Stephens Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $65
Kymera Therapeutics Price Target Announced at $65.00/Share by Stephens & Co.
Kymera Therapeutics Initiated at Overweight by Stephens & Co.
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Raises Target Price to $49
Express News | Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $49
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $53
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)
UBS Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $74
Kymera Therapeutics Is Maintained at Buy by UBS
Express News | Kymera Therapeutics Inc : UBS Cuts Target Price to $74 From $80
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report
No Data